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Executive summary 
There is a lack of evidence concerning the link between HTA and outcomes in terms 
of health improvements.  This work proposes a framework for assessing the impact 
of HTA.  This impact assessment is a necessary step in then better understanding 
the value for money of HTA bodies.  We emphasis that this is still a work in progress. 
iDSI has developed a theory of change-based framework in order to evaluate the 
impact the iDSI has on institutional strengthening – leading to ‘better decisions’ for 
‘better health’.  This framework recognises that there is a complex translation 
process between better decisions and better health dependent on many assumptions 
about local factors and systems, including linkage between decisions and budgets, 
delivery, implementation, and data accuracy.  Work has been undertaken over the 
last 6 months developing a methodological approach for measuring the impact of 
health technology assessment (HTA).   Two case studies are used to illustrate the 
approach. 
At the core of impact assessment is a requirement to link causes and effects, to 
explain ‘how’ and ‘why’ and to identify – and thus improve or adapt - mechanisms 
leading to impact.  Policy makers also want to know ‘to what extent’ or ‘the 
magnitude of impact’.   The framework developed adopts an economic approach 
nested in theory of change as a means of both quantifying the magnitude of impact 
(utilising economic models) as well as explaining why and how impact happens 
(drawing on theory based approaches) in order to reinforce learning as to how to 
improve our response and optimise the use of HTA to have the greatest impact in a 
given context.   This should also enable us to capture and explain wider impact – 
perhaps more intangible aspects which cannot be easily quantified.  This may also 
possibly increase policy-makers’ ‘buy-in’.  
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The work has been presented at an iDSI workshop, York and HTAsialink, Taipei in 
May 2015 and at iHEA, Milan in July 2015.  Feedback received has been around the 
following issues, and these are reflected on below and in the report.  
• The appropriate impact measures of HTA:  on health gains or on the decision 
making process, recognising that there are different types of decision making, 
namely on priority setting versus planning.  A recommendation was made that 
we consider breaking impact down into two stages – firstly, impact on the 
decision making level and secondly, on population health.  
• The distinction between reimbursement decisions and changes in healthcare 
practice, and the extent to which the implementation should be incorporated. 
• How to capture wider impact, for example, productivity. How to capture iDSI 
activities, for example, what do better institutions look like? 
• The difficulty in specifying the counterfactual. 
• Limitations by not evaluating a range of research / package of interventions. 
 
Ultimately, if we want to hold decision makers accountable for lost impact on health, 
and understand whose health has benefited/dis-benefited, we need to measure 
impact HTA at this level.  However, our methods aim to also capture outcomes on 
decision making, for example, in terms of how issues arrive (or not) on the policy 
agenda, how options are chosen as well as implementation which is likely to hold 
additional challenges for low- and middle-income countries (LMICs) around human 
resources and infrastructure - and all of which can positively or negatively affect the 
impact of HTA.  We also acknowledge that some do not consider HTA to be about 
implementation: HTA is about ‘depth not breadth’.  Rather, HTA is a priority setting 
tool whereby decisions should not be constrained by implementation issues versus 
planning processes. Again, we show how we can capture impact on priority setting 
as well as impact from implementation in our framework.   
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Finally, we assume the principles will be the same in LMICs and high-income 
countries (HICs).  A main difference may relate to the availability of evidence. 
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1.  Literature review 
Effective decision making at multiple tiers is a prerequisite for high performance in 
health care (1).  Much research has been undertaken on establishing what factors 
influence improved decision making (2, 3) ; this includes good governance structures, 
expertise, political and institutional factors, resources, participation, and capacity (1, 
4).    
However, how such influences on decision making interact with local context and 
health systems, leading to impact on health outcomes is less explored and arguably 
of critical importance in healthcare settings in LMICs (1).  It would appear that 
evaluations of HTAs have mainly focused on processes and decision-making rather 
than outcomes.  Straus et al (2004) are quoted in (5) “…a review of the existing 
literature on HTA reveals a startling lack of depth, particularly on the impact HTA has 
had on health-care budgets, efficiency, and on societal health outcomes. Indeed one 
commentary noted that whereas the previous 10 years have been well-spent on 
building the HTA/EBM infrastructure and evidence base, the next 10 should focus on 
the outcomes.”   Another review (6) found that “HTA reports typically do not define 
their impact objectives, that is – the effects they would like to achieve (for example, to 
influence coverage decisions, support guideline formulation or change routine 
practice)…the stated objectives or research questions are scientific, related to the 
technology being assessed rather than describing the expected role of the HTA 
itself”.   
Evaluations have been undertaken to establish what HTA has achieved (2). 
European country case studies have found marginal impact of HTA and that for HTA 
to have greater impact in the future, there is a need to better integrate local 
practitioners into the HTA process; and for greater influence at the policy-making 
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level, assessment and appraisal to be incorporated within a common structure to 
provide necessary incentives for policy makers to consider the science and that the 
HTA agencies will need to be handed greater regulatory powers (14).  It is also found 
that ‘on many occasions, such scientific evidence is neglected….discouraging policy 
makers and practitioners from making use of HTA findings’ (15). 
The payback measure (ie what you get back from the investment) has been 
considered to be the most commonly used approach to assess the impact from 
health research (7) as proposed by Buxton and Hanney (8) (9). The payback 
approach has 5 categories of impact:  knowledge production, research targeting and 
capacity building, informing policy and product development, health and health sector 
benefit, and broader economic benefit.  Others have similarly identified different 
levels of impact  (6)  The payback approach has been recommended as the 
approach to assess the NIHR’s HTA programme in the UK – in  the past (10) and 
continues to be recommended for its current evaluation (11).  The payback approach 
confirmed that impact on knowledge generation was more easily quantified than that 
on policy, behaviour or especially health gain.   Two HTA impact publications related 
to these evaluations are due to be published imminently:  an impact evaluation of the 
NIHR Health Technology Assessment Programme, 2003-2013 - a multi-method 
evaluation - is due to be published in October 2015 alongside a systematic review of 
impact measures in health technology assessment in August 2015.  The protocols 
can be accessed on the NIHR website (12)1 and (13)2 
Impact can be defined according to whose perspective is being considered.  Impact 
may be defined at many levels with different measures of impact: at the policy level, 
                                               
1
 This has just been published end Aug 2015.  12 case studies are used to illustrate impact 
using the payback approach.  The need to cost for implementation and impact achieved by 
HTA NIHR’s relationship with NICE’s decision-making process are highlighted. 
2
 Publication date now pushed back to May 2016. 
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in terms of clinical behaviour and also impact on health gains or wider benefits to 
patients. Measuring health in terms of health gains necessarily requires 
implementation to be addressed, this being the means by which to translate evidence 
into impact on health.   Much research has been undertaken around facilitators and 
barriers in implementing the findings of HTA (17) and how policy actually changes 
practice (2):  the main elements to successful implementation being: a) defining a 
clear policy question; b) defining a clear research question; c) making 
recommendations commensurate with the evidence; d) identifying the 
implementation mechanism; e) paying attention to incentives and disincentives; and 
f) clarifying the roles and responsibilities of the various parties (17). 
Recommendations have been made as to how these factors can then be used to 
improve impact, notably that key stakeholders (for example, patients, providers and 
industry) are adequately involved; decision-makers give a prior commitment to use 
assessment reports (and assessments meet their needs); the necessary resources 
are available for implementing decisions;  there is transparency in the assessment 
and decision-making processes; and collaboration, knowledge and skills are 
transferred across jurisdictions (3).   
A conceptual model of health care systems and HTA is presented by Towse et al 
which depicts how the impact of spending levels, degree of centralisation, impact and 
the focus/breadth of HTA results in outcomes; the ‘impact of HTA ...depends on a 
wider set of health system factors that define the underlying architecture of the health 
care system…The regulatory framework and reimbursement systems…define the 
incentives and behaviours of the actors in the system” (16).   
For countries with greater capacity constraints, it is important to consider the total 
available budget, available human capital (trained HTA evaluators), accessibility of 
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data, and the capacity of the health care system to use the results (3, 18).  Given the 
lack of HTA capacity and its use in LMICs (19), tools have been proposed in the 
absence of a formal HTA structure (20).   Also, given the poor infrastructure in many 
LMICs, ‘macro HTA’ aimed at developing performance in the healthcare system may 
be of greater importance in this context than in HICs where HTA has had a more 
traditional ‘micro HTA’ role of appraisal of single/related technologies (21).  
In conclusion, it is clear that the impact of the HTA depends in large part on the 
quality and transparency of the assessment and decision making process in addition 
to the broader institutional, political and cultural dynamics.  However, it is also 
evident that the least researched area of HTA is around its implementation and its 
impact on health.   It would appear that the implementation - and impact - of HTA can 
be facilitated if there are: appropriate policy instruments and regulatory levers 
available; a prior commitment by decision-makers to use assessment reports in 
decision-making processes; available resources to implement decisions; stakeholder 
involvement; and transparency in both the assessment and the decision-making 
process.  It nevertheless remains a challenge and one of the least developed areas 
of the overall HTA process (3).   
From this initial brief overview of the literature, our sense is that the evidence base of 
the impact of HTA on health outcomes is very weak/lacking in HICs, let alone LMICs.  
Given the lack of an evidence-base in the literature, this report proposes a 
methodological platform to understand better the mechanisms by which HTA can be 
effectively implemented into policy and practice, underpinning a ‘theory of change’ 
with an evidence-base as to how ‘better decisions’ translate into ‘better health’.  Even 
in the light of poor existing evidence from the literature, our proposed realist 
approach (see below) would allow all evidence, including naturally occurring primary 
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evidence from grey literature within the organisations of interest as material for 
analytical consideration. 
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2. Research question 
Our aim is to develop a methodological approach for measuring the impact of HTA, 
with a focus on applying this learning specifically to LMICs.  We propose a 
conceptual framework which we envisage would help to optimise the use of HTA in 
any given context.  Our focus in this report is on presenting the conceptual 
framework but our intention is to develop or test a programme theory against the 
evidence – proposing a realist methodology.  Our approach would be to start with 
reality in wanting to understand how it works, ie deriving a theory, in this case, a 
‘theory of change’ from the facts or evidence.   
We also hope that in better understanding how and why impact happens, this 
enables international donors and decision makers to make better decisions given the 
local context (22); and that it is not sufficient to demonstrate that the gain in health 
from a new intervention be valued purely by a return on investment but whether the 
value of the health gained exceeds the value of the health (and resources) forgone.  
By drawing on theory based methods, we are also interested in exploring how 
welfare theory underpinning the economic approach (and our rather static decision 
models) can tie into other social science theories on change – and vice versa. We 
are still playing with these ideas as possible informants to the overall approach.  At 
the very least, it should encourage greater interdisciplinary collaboration. 
Finally,  given the particular challenges faced in the context of LMICs, the research 
being undertaken by the iDSI methods working groups will be critical in 
understanding how best to translate the use of HTA into impact on health.  We have 
tried to make explicit the links with this impact research to each of the other methods 
working groups’ research on evidence, constraints and thresholds. 
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3.  The Conceptual Framework 
Figure 1: The Conceptual Framework 
 
3.1 Overview 
IDSI defines impact in terms of improved health outcomes (QALYs/DALYs) and 
observed impact on cost-effectiveness.  We have built on the IDSI framework by 
proposing a methodological approach to assess the impact of HTA on health 
outcomes using the measure of net health benefits (NHBs), ideally, cost per QALY 
gained.  The framework aims to convey the concepts of potential population health 
benefit and realised population health.  The mixed-method framework proposed 
adopts an economic approach embedded in theory of change as a means of both 
quantifying the magnitude of impact (utilising decision models to derive potential 
population health benefit and realised population health benefit) as well as explaining 
why and how impact happens (drawing on theory-driven approaches) in order to 
reinforce learning and optimise the use of HTA to have the greatest impact in a given 
context.   
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We use decision models to generate estimates of the expected cost-effectiveness, 
decision uncertainty associated with each option and the cost of uncertainty (ie the 
potential value of further research) as HTA has, on the whole, represented a move 
from effectiveness alone to an assessment of costs and effects in maximising 
healthcare given the available budget. This is also reflected in the fact that iDSI, in its 
theory of change, measures impact on both health and observed cost-effectiveness.  
We envisage theory based approaches will help to show how and why intermediary 
outcomes (for example, by getting evidence into practice, dissemination and reaching 
the right people) is achieved in order to have an impact on population health. 
Using the initial HTA model based on available evidence, we would predict the 
expected gain in population health from a policy change given best evidence.  This 
would allow the uncertainty and priorities for research to also be considered.  We 
would then want to understand if HTA has changed policy through direct observation 
of policy, and make a best assessment of the counter-factual.  How has that decision 
been realised?  What changes in practice?  Is there a decision to recommend or fund 
or reimburse the intervention?   Have clinicians and/or patients changed their 
practice?  Are there additional costs incurred to change practice? Taking observed 
uptake and implementation, we would calculate the realised expected gain in 
population health given best evidence.  How we explain the difference between 
expected and actual gain in population health could involve more qualitative work 
with relevant stakeholders, drawing on theory based approaches.  The model can 
then be used to define the opportunity cost of not spending money to get something 
implemented – the value of implementation.  This would require evidence on the 
cost-effectiveness of implementation activities.  Finally, by updating the original HTA 
with further evidence from appropriately designed research, what does additional 
evidence suggest about expected and actual gains in population health?   
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3.2 Net health benefits 
The aim is to get over the concepts of potential population health benefit and realised 
population health benefit.  The measure of net health benefits (NHBs) (ideally, cost 
per QALY gained) will be the core information needed to assess health impact.  Net 
health benefits incorporate impact on health as well as layering in costs into a single 
measure.  The cost effectiveness threshold provides a measure of health forgone as 
a result of additional costs following the decision ie the opportunity costs in terms of 
health.  QALY gains are valued at the healthcare service opportunity cost based on 
the original threshold used and presented net of costs.  The potential population 
health benefit is quantified (from the original HTA) using available evidence.  The 
realised population health benefit is quantified using available evidence or 
assumptions or scenarios on the degree of uptake as to how that decision has been 
realise ie what changes in practice.  
3.3 Value of implementation 
Healthcare technologies that are deemed cost-effective (or beneficial) do not 
automatically or immediately get implemented perfectly into clinical practice,  
resulting in opportunity losses, due to  constraints potentially on the supply and /or 
demand side but also at the legislation and priority setting level (23).  We draw on 
value of implementation to show the difference in impact with and without further 
implementation (24).  The difference between the benefits yielded by the treatment 
given existing implementation levels and those generated with full implementation is 
the ‘expected value of perfect implementation’.  It is this value that informs the upper 
bound on the value of what we should be prepared to invest/or on reimbursing 
implementation strategies to improve implementation of (or adherence to) cost-
effective interventions to generate greater impact (25).  Imperfect implementation 
clearly reduces the total benefit of an adoption decision in the population and has an 
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impact on the estimated value of further research.  Methods for calculating the 
expected value of further information which accounts for the reality of less than 
optimal implementation have been proposed (26).  
Costs of implementation and/or the extent to which adoption requires infrastructure 
changes in LMICs in particular, must, in principle, be considered when comparing 
interventions but will vary from setting to setting.   This is considered part of the 
‘constraints’ agenda being undertaken by another iDSI Working Group.  To what 
extent the original HTA ignores or addresses information about a technology’s 
implementability (and whether decisions on implementation strategies should be 
made sequentially (27) or simultaneously (25)), should be captured in our framework 
in terms of realised net health benefits.   
3.4 Theory based approaches  
3.4.1 Formal Theories 
We want to identify tensions and understand the barriers and facilitators to impact 
(28, 29).  To this end, we propose building on the theory of change approach 
developed by iDSI and also introduce a realist methodology to enable us to build up 
a programme theory.  Realist approaches allow the incorporation of theory (in this 
case, a theory of change) and will also provide a framework for evaluation. 
It has been suggested that many policy programmes lend themselves to the explicit 
testing of a dual Theories of Change/Realistic Evaluation model (30). Although the 
latter is relatively untested in the field of healthcare, it is gaining support and use from 
organisations such as the NIHR and DFID (31, 32).  Guidance for researchers in the 
use of a realist approach in healthcare is currently being developed (33).  By using a 
realist methodology and drawing upon theories of change, we aim to better capture 
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the multi-dimensional aspect to the impact of HTA:  at the individual technology level, 
at the HTA and the decision making levels, and their interactions.   
Theories of change (ToC) is about the identification and confirmation of causal 
processes – an explanatory pathway of change.  Developed by the Aspen Institute 
(Connell et al, 1995; Fulbright-anderson et al, 1998), it is process orientated as it 
follows the pathway of a programme from its initiation through causal implementation 
links (to explain how and why the desired change is expected to come about) until 
intended outcomes are reached.  The ToC is developed through collaborative 
stakeholder engagement.  It requires measurement along the way of all outcomes 
that must be achieved before the long term outcome, in our case, impact on 
population health. 
Other theories explored include implementation science but our understanding is that 
this operates at a more micro/individual level than the overarching understanding of 
change we are trying to capture.  Organisational cultural and critical realist theories 
are about the interplay and tensions between knowledge, power and social control.  
The premise being that organisations do not make decisions but people with biases, 
motives, histories etc make the decisions but are required to do so within the 
confines of power structures (like organisations and governments). The latter 
especially, are congruent with the philosophy of realist evaluation.  
We envisage one of the outputs of the process would be a ‘Theory of Change’ map 
informed by the richness of what we find, for example, any contextual issues and 
specific barriers related to that particular HTA – and that the methods proposed 
should help (re-)inform such a mapping process/framework.    
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3.4.2 Realist Evaluation Methodology: a theory-based 
methodological approach  
A realist approach (Pawson, Tilley 1997) recognises that there are many connected 
variables operative at multiple levels, and within varying contexts, with varying 
resources available to help understand intervention and policy changes success or 
failure. As such, realist evaluation lends itself to the purpose of evaluating complex 
social interventions. This approach thus contributes to knowledge beyond traditional 
‘does the programme work?’ questions and cause-effect analysis, to understanding 
what it is about a programme that makes it work, and allows for the identification of 
supporting factors – proximate, contextual, historical.  Adopting a realist methodology 
would allow us to build up a programme theory by testing and refining hypotheses to 
explain the routine embedding of new practices in healthcare by reference to the role 
of context, mechanisms, outcomes (34).  For example, the system in which HTA 
operates will already have policies, procedures, ways of doing things, values and a 
challenge to generalisability will be that context is likely to influence the impact so 
incorporating this is key.  As HTA works differently in different contexts and impact is 
likely to be achieved through different change mechanisms, it is unlikely that HTA 
can be replicated from one context to another and automatically achieve the same 
outcomes.  Good understanding about what works, for whom, in what contexts, and 
how – are, however, portable. These portable explanations can be presented as 
explanatory theories. Mechanisms are at the heart of the explanation: it is not 
interventions, but people who change problem situations. Mechanisms are usually 
implicit, and therefore require theory to inform how contexts could trigger 
transformative variables. In the case of HTA, one could envisage impact is achieved 
through an interaction between policy makers, practitioners, their rationale and the 
resources for implementation. However, empirical work would refine and specify this. 
Realist evaluations’ strength is its explanatory basis, to make sense of the complex 
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processes underlying programmes by formulating plausible explanations ex-post and 
thus building upon what is known and learning while doing becomes important.  It 
operates between the necessary workings ‘on the ground’ (at the individual 
technology level?) and efforts to explain social behaviour, social organization and 
social change (at the HTA decision making level?).  We propose this could help 
better understand how iDSI activities (on governance, accountability, institutional 
support, democratic and stronger institutions) shape or contribute to outcomes and 
impact. 
Whilst data sources and methods are left open to choice, the evaluator maps 
out/hypotheses a series of potential mini theories (the casual and situational triggers) 
that relate the context of a programme to the multiple mechanisms by which it might 
operate to produce different outcomes. This would draw upon what is already known 
about factors influencing the implementation and impact of HTA (see literature review 
Chapter 1).  However, in realism, you are also looking for experiences observed in 
your data so that new knowledge is identified.  A realist methodology would allow all 
data and impact to be captured.  This could include literature, interview data, policies, 
written recording of meetings, and feedback. Thus, we could address feedback 
received that the impact of HTA should be captured not just on distal outcomes 
(population health) but also on more proximal outcomes, such as the impact on 
decision-making, and analyse this using realist evaluation principles of extracting 
context-mechanism-outcome configurations of variables at play, and iterative, 
participative, and collaborative approaches to interpretation. 
Figure 2 below provides an example of how we might use theories of change as a 
framework for analysis of all evidence.  It is a suggested example of Theory of 
Change ie our programme theory, and using a realist method  to ‘home in’ on 
mechanisms at play which are in turn, likely to differ by the context of the HTA. 
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Figure 2: Programme Theory 
 
3.5 The counterfactual 
Finally, the issue of the counterfactual needs to be addressed.  In the studies where 
payback methods were used, it was noted that they were unable to identify the 
counterfactual (7) and the difficulty this presents (2).  Whose health has benefited 
and whose health has dis-benefited? The relates to the hypothetical or unobservable 
counterfactual ie what would have happened without the HTA process  - would policy 
would have changed anyway?  The issue is the extent to which something changed 
(policy change) conditional on the HTA so we need to know something about if the 
HTA had not happened, what the effect is.  It is possible to look at different scenarios 
given the status quo/treatment at the time of the HTA/before the decision and what 
would have happened had the HTA not taken place.   
As well as what would ‘standard care’ be had the decision not been taken, this is also 
partly about thresholds (how much health are we forgoing).  The framework is 
predicated on the threshold representing opportunity costs, and we make explicit the 
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assumption that the threshold originally used in the decision reflects the opportunity 
cost.  Whatever the threshold that was used for the original decision will be the 
starting point for the impact estimates (with discussion and sensitivity analysis 
around what if it is different).  It is not in the scope of this work to estimate an 
appropriate opportunity cost threshold.  If one does not exist, we will explore the 
sensitivity of impact using a range of possible thresholds.  This will tie into the work 
being undertaken around thresholds by one of the iDSI technical Working Groups, 
quantifying what is displaced to enable the net population health impact of the 
intervention to be determined. 
However, “because the realist analysis uses mainly intra-programme comparisons 
(i.e., comparisons across different groups involved in the same programme) to test 
the initial theory, a realist evaluation design does not need to construct comparison 
groups. Rather, the refined programme theory will be tested subsequently in a 
different context in a next study. Often the case study design is used, whereby case 
selection is typically purposive, as the cases should enable ‘testing’ of the initial 
programme theory in all its dimensions” (35)  
Finally, should we include the cost of HTA in an impact assessment?  This is 
considered unlikely to be a major issue.  There are lots of positive externalities likely 
to arise from HTA, such as better payment mechanisms, better information, better 
administration etc.  Nevertheless, there is a need to consider ways in which 
international cooperation, global public goods, donor funds (and iDSI) can 
help minimise costs.   Importance of time it takes to do an HTA (hence delaying, for 
example, good vaccines getting into practice) may be viewed as an obstacle. It has 
been suggested that this could be quantified using option pricing methods as a way 
of reconciling investment costs, uncertainty and delay into a single coherent 
framework (ref iDSI correspondence, Pete Smith).  
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Figure 3: Summary of conceptual framework 
 
We would hope that through this work, policy makers would be in a better position to: 
• measure the actual impact of an HTA on health outcomes vis-à-vis potential 
impact (quantified in net health benefits) through monitoring of uptake and 
coverage; 
• assess the value of what the health service provider can invest in (cost-
effective) implementation strategies – and the cost of not doing so - to ensure 
utilisation of the intervention by all those eligible (value of implementation); 
• understand better the mechanisms by which HTA can be effectively 
implemented into policy and practice in any given context to optimise its use 
and impact. 
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4.  Case Study - Myanmar 
4.1 Background 
Myanmar’s Maternal and Child Health Voucher Scheme (MCHVS) provides new 
demand-side health financing options with the goal of improving the utilisation of 
MCH services, especially for poorer households.  GAVI’s Health System 
Strengthening (HSS) initiative in Myanmar comprises three major elements, including 
financing reforms, human resources and infrastructure to tackle the supply-side of 
services.  There is, however, a need to also tackle the demand side.  The MCHVS 
subsidies pregnant women to receive 4 ante-natal care visits (ANC), delivery and 
postnatal care (PNC) free-of-charge in order to help women overcome financial 
barriers to access as well as raising awareness of the benefits of ANC and delivery 
with skilled birth attendants (SBA).  
4.2 The Health Technology Assessment 
The HTA consisted of a feasibility study (37) and ex-ante economic evaluation based 
on three visits from May 2010 – March 2011 by HITAP in collaboration with 
Myanmar’s Ministry of Health (MoH) and WHO’s South-East Asian Region Office 
(SEARO) (38).  Decision analytic modeling was undertaken to estimate costs, heath 
outcomes and cost-effectiveness.  Full details of the model have been published (36-
38). 
The model incorporates baseline levels of ANC (73%) and SBA (51%) uptake from a 
community survey conducted as part of the feasibility study and country level 
epidemiological data on the current maternal health status in Myanmar.  Parameters 
relating to the relative risk of high-risk pregnancy and the relative risk reduction on 
maternal and neo-natal morbidity and mortality associated with ANC and SBA was 
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informed by the literature, predominantly taken from other countries.   Costs are 
taken from a survey conducted during the feasibility study.  The effectiveness of the 
voucher scheme is based on the price elasticity of demand (Ed) for ANC and SBA 
services in response to a change in price.  This was informed by data from another 
country with a similar economic status.  Impact is then modelled as the number of 
lives saved and DALYs averted for both mother and child.  Using a conservative 
value of 0.2 for Ed and 100% voucher cost recovery for the women in the base case, 
the intervention was found to be cost-effective at a threshold of one GDP.   
A closely monitored pilot study was recommended to ensure that parameters and 
assumptions were revised before scaling up the programme nationwide.  This was 
initiated in Yedarshey township in May 2013.  A mid-term review at 6 months (38) 
was undertaken of the pilot in January 2014 by HITAP, MoH and WHO.  This review 
did not update the economic evaluation and modelling but did include developing a 
theory of change model (Figure 2) 
Figure 2: Theory of Change MCHVS 
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4.3 Assessing Impact 
4.3.1 Potential impact 
The model was updated to incorporate evidence obtained from the 6 month mid-term 
review of the pilot scheme (Table 1). In particular, the feasibility survey samples had 
a much higher rate of ANC uptake (73%) than the national average (56%).  It was 
possible that hard-to-reach individuals who would not receive ANC and delivery 
services were unlikely to have been included in the feasibility study. 
Table 1: Parameters 
Parameters Feasibility 
study 
*Pre-
implementation 
pilot 
Review of 
pilot at 6 
months 
Baseline probability of 
seeking ANC with 
SBAs 
0.73, (0.03) – 
mean, SE 
Community 
survey 
1.81 average 
visits 
0.56 
2.37 average 
visits 
Baseline probability of 
delivery with SBAs 
0.51, (0.04) –
mean, SE 
Community 
survey 
0.67 0.77 
Effectiveness of 
CHI/elasticity of 
demand 
0.2 
Nepal study, 
2005 
0.2 0.2 
Average immunisation 
obtained per infant: 
Vaccinations 
(DPT/OPV) 
 - 2.45 2.99 
 
Using the decision model, potential NHBs were estimated using the original 
parameters from the feasibility study and then revised to give a better indication of 
impact using best available evidence at that time from the pilot.  This was scaled to 
the pilot level ie coverage of 11,532 pregnant women in Yedashey township.  Using 
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the original threshold used of 1 GDP, the NHBs associated with full implementation 
are presented in Table 2.   
Table 2: Potential net health benefits 
 
Note that the study refers to the original model as an ex-ante evaluation and the pilot 
review as an ex-post evaluation.   We have continued to use this terminology but 
make clear the distinction between up-dating the model with new evidence with what 
is now known to be different, and an impact assessment.   
4.3.2 Realised impact 
Using the monitoring data collected from the 6 month review of the pilot, realised 
NHBs (actual impact) and the expected value of perfect implementation (maximum 
potential impact) were calculated.   
The mid-term review reported an increase in SBA uptake to 77% (from 67%).  Taking 
the total population eligible for treatment (N = 87%, ie 67% baseline + 20% increase 
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in uptake modelled) and the proportion of these patients already receiving the 
intervention (p), the current value is defined as:   
N * p * NHB = 11532 * 77% (of 87%) * 0.05 = 510 NHBs 
 
The expected value of perfect implementation represents the maximum possible gain 
from implementation of the health care technology and is calculated as the difference 
in value of all eligible women being covered and those currently receiving the 
intervention ie the current value.  Figure 3. 
Figure 3: The expected value of perfect implementation 
 
The shortfall in NHBs indicates that coverage, and thus impact, is sub-optimal.  This 
provides a ceiling value for investing in implementation strategies ie that the cost and 
magnitude of change achieved by an implementation method does not load 
treatment cost-effectiveness to such an extent that normal bounds of cost-
effectiveness are exceeded.  
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The expected value of actual implementation represents the actual gains from an 
implementation initiative resulting from those patients receiving the intervention who 
would not have done so otherwise (as initiative will not necessarily result in perfect 
implementation), where α is the proportion treated with the initiative. 
n * α * NHB – n * p * NHB  
 
Finally, an implementation initiative is worthwhile if its benefit in terms of increased 
utilisation of the intervention (the expected value of actual implementation) is greater 
than its opportunity cost.   This is the incremental net benefit of the implementation 
initiative. 
n * α * NHB – n * p * NHB  - Implementation Cost / λ 
4.4 Discussion and next steps 
We understand there is an external evaluation of the pilot at 12 months currently 
being undertaken.  Should tying this work into the results of that evaluation help 
serve evidencing the planned expansion of the work to GAVI, we are very happy to 
collaborate.  There is mention of possibly expanding the scheme to include further 
vaccination coverage, in particular measles, mumps and rubella (MMR) vaccines at 9 
and 18 months.   Potential impact could be re-estimated using models such as, for 
example,  LiST (The Lives Saved Tool) (40) which specifically incorporates 
vaccinations. Its general principle is to model scale-up of multiple MNCH 
interventions over time at a population level.  We also envisage one of the outputs of 
a future process could be a ‘Theory of Change’ map re-informed by the richness of 
what is found relating to, for example wider contextual issues, impact on financial 
protection and poverty reduction, quality of services and unintended outcomes.  
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Finally, the original analysis did not employ a probabilistic sensitivity analysis (PSA) 
though this was undertaken for a publication later (36) with changes, namely the cost 
of production of voucher was updated,  and low birth weight split into anaemia and all 
sequelea.   We use the original model. 
Key considerations: 
• Given observed uptake and implementation, realised impact is sub-optimal 
compared to the potential impact modeled. 
• Can the HTA / intervention’s theory of change help us to understand why this 
shortfall exists, does it need to be re-informed? 
• We provide a ceiling value of investing in (cost-effective) strategies to improve 
implementation and thus impact. 
• What is known about the cost-effectiveness of relevant implementation 
strategies in this context to improve impact? 
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5.  Case Study – Thailand  
5.1 Background 
HPV vaccines are effective against two oncogenic subtypes of HPV infection, have 
good potential to avert incidences and save the treatment costs of cervical cancer.  In 
Thailand, HPV vaccine was found to not be cost effective relative to the 
recommended threshold.  The most cost-effective policy option was to improve the 
performance and coverage of the existing screening programmes.  There is an 
existing decision model and this case study enables us to look at the impact of a 
decision not to adopt.  The continuing advocacy for HPV vaccination provides a 
conducive context for the government to strengthen the screening service provision 
as it is the only affordable choice currently available, and for us to look at impact 
around strengthening of the existing screening programmes.   
5.2 The Health Technology Assessment 
At the then current [2007] price, HPV vaccinations for girls aged 15 years compared 
with the current national policy of Pap smears for women aged 35-60 years every 5 
years was found to be not cost-effective at the recommended threshold of Bt160 000 
per QALY as set by the Subcommittee for Development of the Health Benefit 
Package and Service Delivery of the National Health in Thailand.  Instead, visual 
inspections with acetic acid (VIA) every 5 years for women aged 30-45 years, 
followed by Pap smear test every 5 years for women aged 50-60 years was the 
dominant screening strategy compared with doing nothing (at 20% uptake of 
screening) (41).  This screening strategy is now national policy with a coverage aim 
of 80%.  Combined vaccination and screening was found to be more cost-effective 
than vaccination alone.    
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5.3 Assessing Impact 
5.3.1 Potential impact 
Using the existing model and published paper on the HPV health technology 
assessment, potential net health benefits were calculated for each of the following 
comparators: 
Existing screening strategy: Pap smears for women aged 35-60 years every 5 years 
Recommended screening strategy: VIA every 5 years for women aged 30-45 years, 
followed by Pap smear every 5 years for women aged 50-60 years 
Vaccination: HPV vaccinations for girls aged 15 years + VIA every 5 years for women 
aged 30-45 years, followed by Pap smear every 5 years for women aged 50-60 
years. 
Table 3: Cost and QALYs, NHBs 
Strategy Total costs Bt Total QALYs NHBs 
Existing screening @ 20% uptake $9090 28.07 28.01 
Recommended screening @ 20%  $8819 28.08 28.02 
Recommended screening @ 70% $7291 28.10 28.05 
Recommended screening @ 80% $7044 28.10 28.06 
Vaccination @ 100% $18,306  28.13 28.02 
 
Strategy with highest NHB at this threshold is the recommended screening strategy. 
This was then scaled to a population level for both the target level (80%) and the 
current level of coverage of 70% for the recommended screening strategy versus the 
alternatives. 
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Table 4: Population level NHBs 
Strategy Population 
eligible  
Coverage NHBs at population 
level 
Existing screening (1) 14,000,000 20% 78,428,000 
Recommended screening (2) 16,000,000 20% 89, 664,000  
Recommended screening (2) 16,000,000 70% 314,160,000 
Recommended screening (2) 16,000,000 80% 359, 168,000  
Vaccinations (3) 19,000,000 100% 532,380,000 
 
(1) http://pubmedcentralcanada.ca/articlerender.cgi?accid=PMC2705003 
(2) Estimated in relation to the other numbers 
(3) http://www.indexmundi.com/thailand/age_structure.html 
 
 
 
5.3.2 Realised Impact 
Our understanding is that whilst there has been a strengthened screening strategy, 
coverage remains just below the target level, at around 70% (ref. 
http://www.who.int/whr/2013/report/en/). 
This, however, would still represent a potential gain of over 10,000 000 QALYs in 
terms of impact upon population health by having moved from the existing screening 
strategy to the dominant screening strategy even if coverage had remained at 20%.. 
Not achieving the target of 80% screening coverage results in unrealised impact to 
the magnitude shown in Table 4 above. 
5.4 Discussion and next steps 
A qualitative assessment was undertaken by HITAP (42) to better understand why 
the government’s original attempt to scale up the new strengthened screening 
programme had failed to increase implementation.  It was found that despite good 
evidence, the scaling up of the screening service did not achieve any impact as it 
was largely driven by political factors and was not well devised largely due to the 
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political crisis of mid-2008.   There had been no participation from stakeholders such 
as clinical experts and health providers during the policy formulation and 
implementation process, and no solutions to counter the already known obstacles to 
the provision of screening services were identified.  No operational plan was in place, 
nor any monitoring and evaluation of the service extension.   
Even though scientific evidence concerning the safety, efficacy, effectiveness and 
value for money of the policy option, with political will, adequate financial support and 
a well-established infrastructure, the scaling up of the screening service in Thailand 
did not achieve its promise in its explicit phase of implementation.   Whilst often 
argued that the main obstacles to health system development in resource-limited 
settings are inadequate financial and human resources, and the lack of relevant and 
reliable evidence to guide proper policy decisions (43), this illustrates the potential 
danger of developing models and policies in isolation.  We propose that developing 
models in a theory of change process may help support its implementation and 
impact of the HTA. 
Finally, we noted that there are other papers published (44-46) with conflicting 
results, and have considered possibilities as to why: comparators (9-12 years versus 
starting at 15 years), threshold values, cost and efficacy of vaccine (79% - 100%), 
outcome measure (DALY, QALY, lives saved), discounting, parameters on incidence, 
vaccine coverage, and costs of care of cancer treatment.   The aim here was not to 
critique the existing model but to use it as a way of illustrating how we might assess 
impact.  It would be useful to update the HITAP model with updated vaccine prices 
and estimated current coverage of both vaccination and screening. 
Key considerations: 
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• Realised impact is sub-optimal given observed uptake and implementation 
compared to the potential impact. 
• We provide a ceiling value of investing in (cost-effective) strategies to improve 
implementation. 
• What is known about the cost-effectiveness of implementation strategies to 
improve impact? 
• Undertaking HTA in a theory of change process may help support its 
implementation and impact. 
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6.  Future work 
6.1 Data linkage 
We could explore the possibility of data linkage to validate this work by enabling 
linkage to health outcomes.  Countries with good data linkage and the established 
use of HTA might be Scotland (linkage to Scottish Morbidity Records), or possibly 
Taiwan ie this is only likely to be available in higher income countries but still with 
wider learning opportunities from an HTA impact assessment applicable to other 
countries. 
6.2 iDSI’s monitoring and evaluation framework 
We understand the analytical approach will be incorporated within iDSI’s monitoring 
and evaluation (M&E) framework, led by Itad.   
Our theory of change refers only to how and why policy decisions get implemented in 
practice as opposed to the wider iDSI theory of change that Itad is developing.  We 
see this work fitting into Itad’s theory of change in terms of what do better decisions 
and better health mean in quantitative terms, and how do we get from better 
decisions to better health. This speaks well to the assumptions at this level made in 
Itad’s framework around the implementation of decisions, and uptake by patients and 
clinicians.   
Unlike Itad’s framework, we are not monitoring the implementation of iDSI activities.  
However, the methods proposed here would involve ongoing measuring along the 
way of an HTA, and would require size of the eligible patient population and changes 
in utilisation rates in addition to usual cost and effectiveness measures in order to 
monitor uptake and coverage.  If an impact assessment was planned, this would also 
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require more qualitative data to inform such an evaluation.  An example of different 
indicators of uptake and coverage is presented below which could be evidenced by 
(M&E) data.   
Perhaps the biggest limitation to applying this framework is knowing something about 
the cost-effectiveness of implementation strategies.   
Figure 3: Monitoring and evaluation 
 
 
 
 
6.3 The case studies 
It would be valuable to be involved (ideally) from the start of an HTA process.  
Regarding how beneficial it is to continue with the same two case studies, we would 
ask HITAP and iDSI as to what might be considered to be the most useful approach.   
The timeframe has meant the work on these studies has been confined to desk-
based research.   Future work would incorporate mixed methods and the theory 
based approaches. 
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6.4 Systematic review 
A more thorough review of the literature would need to be undertaken.  However, as 
there is a systematic review due to be published shortly on impact measures and 
models used in HTA impact assessment (13), this should greatly help to inform future 
work. 
6.5 Package of interventions 
A limitation has been raised that whilst we are considering the impact of a single 
technology/intervention, it would be more realistic to measure a package of HTA.   
Single HTA appraisals reflect the nature of economic evaluations.   Alternative 
options might be to consider the impact of HTA in developing healthcare packages 
for Universal Healthcare Coverage (47) (48, 49) and/ or to consider HTA at a more 
macro level in LMICs (21). 
Finally, we will follow up with those who provided contact emails to our impact survey 
at HTAsialink. 
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